CD19/BCMA CAR-iNK cell therapy (Tome Biosciences)

N/A

Report date: 2024/06/03 16:43:49

Base Information

Drug NameCD19/BCMA CAR-iNK cell therapy (Tome Biosciences)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionNatural killer cell replacementsB-lymphocyte antigen CD19 modulatorsB-cell maturation protein modulators
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTome Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesTome Biosciences Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A